Dr David Taussig
Consultant Haematologist MRCP, FRCPath, PhD
Available at: Sutton
- acute myeloid leukaemia (AML)
- acute lymphoblastic leukaemia
- chronic myeloid leukaemia
- high-risk myelodysplastic syndromes
Dr Taussig has both a private and an NHS practice at The Royal Marsden. He is a Consultant Haematologist with a specific focus on acute leukaemia (acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia). He also treats patients with chronic myeloid leukaemia and myelodysplastic syndromes.
He qualified from the University of London (Imperial) and undertook training in haematology at St Bartholomew's hospital, London. He completed his PhD in the laboratory of Dr Dominique Bonnet at the Cancer Research UK London Research Institute, Lincoln's Inn Fields where he studied leukaemia stem cells in acute myeloid leukaemia.
He showed that the prevailing view of leukaemia stem cells was an oversimplification in two well cited publications (Taussig et al Blood 2008, Taussig et al Blood 2010).
He undertook post-doctoral research within the context of an MRC Clinician Scientist Fellowship at St Bartholomew's Hospital where he was appointed as a Consultant Haematologist in 2006.
He showed that acute myeloid leukaemia induces bone marrow failure by preventing normal hematopoietic stem cells from differentiating (Miraki-Moud et al PNAS 2013). Subsequently he has been studying the role of the amino acid arginine in the growth of AML. He is a member of the NCRI AML working party.
He has a laboratory in the Centre for Molecular Pathology researching the biology of acute leukaemias with a focus on acute myeloid leukaemia. He is a co-investigator on a CRUK Programme grant investigating poor risk AML with collaborators at Barts Cancer Institute, the Francis Crick Institute and Birmingham University.
He collaborated with ICR researchers to develop a novel Aurora Kinase and FLT3 inhibitor (that had been created at the ICR) for the treatment of leukaemia (Moore et al Blood Advances 2020). He is now leading a clinical trial of this drug in patients with AML.